atai Life Sciences to Participate in September Investor Events

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September:

• Citi’s 17^th Annual BioPharma Conference in Boston
  
  Format: Industry Panel
  
  Date and Time: Wednesday, September 7^th, 10:30 a.m. ET – 11:15 a.m. ET
  
  Conference Link:

• H.C. Wainwright’s 24^th Annual Global Investment Conference in New York City
  
  Format: Company Presentation
  
  Date and Time: Tuesday, September 13^th, 11:00 a.m. ET – 11:45 a.m. ET
  
  Conference Link:

• Cowen’s 2^nd Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
  
  Format: Industry Panel
  
  Date and Time: Monday, September 19^th, 3:05 p.m. ET – 4:05 p.m. ET | 4:15 p.m. ET – 5:15 p.m. ET
  
  Conference Link:

• Jefferies’ 1^st Annual Psychedelics/Emerging Novel Treatments for Mental Health Summit in New York City
  
  Format: Company Presentation
  
  Date and Time: Thursday, September 22^nd, 9:30 a.m. ET – 10:15 a.m. ET
  
  Link: TBA

The presentations and archived webcasts will also be accessible in the  section of atai’s website where they will be available for up to 90 days.

About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit

Forward-Looking Statements

These presentations may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any expressed or implied statements contained in these presentations that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as updated by our subsequent filings with the SEC, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information

Investor Contact:

Stephen Bardin

Chief Financial Officer, atai Life Sciences

Email:

Media Contact:

Allan Malievsky

Senior Director, External Affairs

Email: